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Abstract.Venous leg ulcers are common in subjects with chronic venous insufficiency. The increased intraluminal pressure causes7
alteration of the skin microcirculation, leukocyte activation and release of proteolytic enzymes leading to ulceration. An impaired8
expression and activity of matrix metalloproteases (MMPs) and their tissue inhibitors (TIMPs) might influence extracellular9
matrix degradation and deposition in chronic venous ulcers with the failure of the healing process. Our aim was to evaluate10
plasma concentration of gelatinases (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in subjects with venous11
leg ulcers before and after the compression therapy. We enrolled 36 subjects (12 men and 24 women, mean age 67.38 ± 12.7 yrs)12
with non-infected venous leg ulcers (CEAP C6), which underwent a color Duplex scan examination of the veins and arteries of13
the inferior limbs and were treated with a multi-layer bandaging system. The ulcer healing was obtained in 23 subjects only (914
men and 14 women). We evaluated, on fasting venous blood, the plasma levels of MMP-2, MMP-9, TIMP-1 and TIMP-2 using15
ELISA kit, before and after the treatment. We observed a significant increase in plasma concentration of gelatinases and their16
inhibitors and in MMP-2/TIMP-2 ratio in subjects with leg ulcers in comparison with normal controls. In subjects with healed17
ulcers we found a decrease in MMP-9 and TIMP-1 levels and in MMP-2/TIMP-2 ratio compared to the baseline values, although18
higher levels of all the examined parameters in comparison with normal controls. In conclusion, plasma MMPs profile is impaired19
in subjects with venous leg ulcers and it improves after the healing, persisting anyway altered in respect to healthy controls.20
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1. Introduction21
Venous leg ulcers associated with chronic venous insufficiency (CVI) affect approximately 1–1.5% of22
the general population and are responsible for a severe impairment of the quality of life and for elevated23
costs because of long treatment times [25].24
The etiology of venous ulcers is still unclear, but it has been suggested that ulceration results from25
an increased intraluminal pressure that causes fibrin deposition around the capillaries with consequent26
leukocyte activation and release of proteolytic enzymes, responsible for tissue destruction. Venous leg27
ulcers in fact are characterized histologically by loss of the epidermidis, alterations of dermal cellular and28
matrix structures, inflammation, and by fibrin cuffs surrounding dermal capillary vessels and inhibiting the29
diffusion of oxygen and nutrients to the epidermidis [4, 16]. Compression therapy is the gold standard for30
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the initial treatment of venous leg ulcers: by the application of graduated pressure to the leg, venous return31
improves reducing reflux [3]. As the pathogenesis of venous ulcer is associated with microcirculatory32
alterations and with an inflammatory response, compression stockings may improve healing rates and33
prevent ulcer recurrence [4, 32].34
In the last decade many authors have described an altered pattern of matrix metalloproteases (MMPs)35
and their tissue inhibitors (TIMPs) in chronic venous insufficiency and in venous ulcers of the lower36
extremities [2, 4, 21, 23].37
Matrix metalloproteinases are endopeptidases which activity consists principally of extracellular matrix38
protein degradation by cleavage of internal peptide bonds. They are secreted by all the cells present into39
the vascular wall, and especially by macrophages, and each MMP has a specific target substrate that40
defines its denomination, such as collagenases, including MMP-1, -8, -13, and -18, gelatinases A and B41
(MMP-2 and -9), stromelysin-1 (MMP-3) and -2 (MMP-10), matrilysin-1 (MMP-7) and -2 (MMP-26)42
and metalloelastase (MMP-12) [1, 6, 17]. Most MMPs are secreted as precursors (zymogens) which are43
activated in the extracellular space by several proteases, oxidative stress metabolites, proinflammatory44
cytokines, and membrane-type MMPs. The activity of MMPs is regulated by the four tissue inhibitors45
of MMP (TIMPs): TIMP-1 inhibits MMP-1, MMP-3, MMP-7 and MMP-9, TIMP-2 inhibits especially46
MMP-2, TIMP-3 can inhibit both the gelatinases, while TIMP-4 inhibits MT-1 MMP and MMP-2 [1,47
6, 17]. An imbalance between MMPs activation and inhibition may cause an uncontrolled proteolytic48
activity and an elevated turnover of the extracellular matrix resulting in leg ulcers formation and in49
impaired wound healing.50
In severe chronic venous insufficiency Saito et al. [26] have observed elevated levels of MMP-1 and51
TIMP-1 and increased MMP-2 expression and activity in biopsies obtained from skin areas of venous52
stasis dermatitis, while other authors [33] have found higher concentrations of the active form of MMP-953
in the leg venous blood samples of subjects with CVI in comparison with controls.54
Regarding the role of the gelatinases in chronic venous leg ulcers, Norgauer et al. [24] have shown an55
increased MMP-2 activity and a dermal overexpression of MMP-2 and membrane-tpe MMPs in biopsies56
from lesional tissue, while Moor et al. [22] have found significantly higher levels of active MMP-9 in57
the wound fluids and tissues of non-healers. Mwaura et al. [23] have examined MMP-2 and TIMP-2 in58
the wound fluid before and after 8 weeks of graduated compression bandaging treatment; they observed59
higher levels of MMP-2 and lower levels of TIMP-2 in non-healer subjects, although these data were not60
statistically significant. Beidler et al. [4] have examined a large range of MMPs (MMP-1, -2, -3, -7, -8,61
-9, -12 and -13) and TIMPs (TIMP-1 and -2) in leg ulcer tissue before and after 4 weeks of compression62
therapy and have described elevated MMPs (with the exception of MMP-7) and TIMP-1 levels and higher63
MMP-9 activity in chronic wounds; after therapy, they have observed a significant reduction of MMP-64
3, -8, and -9 expression and a decrease in MMP-1, -2, and -3 in more rapid healing ulcers. Also other65
authors have found higher levels of MMP-1 and MMP-8 in non-healing ulcers’ biopsies and exudates [2],66
differently from Meyer et al. [21], who have observed higher levels of MMP-1 in biopsies from healing67
ulcers compared with resistant ulcers. This finding is unexpected considering that, in vitro, normal dermal68
fibroblasts incubated with chronic venous ulcer exudate have shown an increased expression of MMP-169
and MMP-3 and a reduced synthesis of TIMP-1 [31].70
Up to now, only few studies have examined the plasma MMPs profile in subjects with chronic leg71
ulcers and also the systemic effects of the compression treatment on these markers of inflammation72
[28, 30].73
In this research, we examined the plasma concentrations of the gelatinases and their tissue inhibitors in74
a group of patients with non-infected leg venous ulcers, and in a subgroup of these patients we examined75
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the same parameter before and after the healing of venous ulcers obtained employing the compression76
therapy.77
2. Materials and methods78
We consecutively recruited 36 subjects (12 men and 24 women; mean age 67.38 ± 12.7 yrs) with non-79
infected venous leg ulcers from those with venous diseases (CEAP: C6) referred to our Department.80
Before the inclusion in the study, all the patients underwent a color Duplex scan (CDS) examination81
performed using Philips HDI 5000 ultrasonography device with a 7-MHz probe. The ultrasound exami-82
nation showed the status of the veins (superficial and deep) and of the arteries of the inferior limbs and the83
characteristics of the ulcers (post-thrombotic or varicose). Venous district evaluation was performed in84
supine and orthostatic position, while arterial district evaluation was performed in supine position. Using85
ultrasound examination we diagnosed the presence of superficial, deep valvular or perforating valvular86
incompetence and the partial or total obstruction of the veins. The valvular incompetence was diagnosed87
by the variations of the vein flow direction during the Valsalva and the compression and release maneu-88
vers. We distinguished total from partial obstruction by a duplex definition. In total obstruction, the vein89
lumen is entirely occupied by thrombotic lesion and there is neither Doppler sound nor color-mapping90
imaging. On the contrary, in partial obstruction, we can discern the blood velocity and the color-mapping91
imaging in the vein lumen. We also measured the ankle-brachial index according to the current Transat-92
lantic Intersociety Consensus guidelines to exclude the patients with arteriopathies of lower limbs, in93
which the application of an elastic bandage is not possible. Means and S.D. of laboratory parameters and94
duration of the disease are shown in Table 1.95
The control group consisted of 30 subjects (14 women and 16 men, mean age 41.3 ± 7.4 years) selected96
from the hospital staff; control subjects were free of medical diseases as assessed by clinical history,97
physical examination, electrocardiography, and routine hematological and urine analysis.98
All the subjects gave their informed consent before entering the study and the study was approved by99
the Ethical Committee.100
On fasting venous blood we evaluated the plasma concentration of gelatinases (MMP-2 and MMP-9)101
and their inhibitors (TIMP-1 and TIMP-2) using respectively the Human MMP-2 ELISA and Human102
Table 1
Means ± S.D. and range of the main laboratory parameters and duration of the disease of the
whole group of subjects with chronic venous
Means ± S.D. Range
Glycaemia (mg/dl) 86.19 ± 6.34 76–98
Creatininemia (mg/dl) 0.94 ± 0.09 0.77–1.12
Total cholesterol (mg/dl) 211.36 ± 20.07 123–248
HDL-cholesterol (mg/dl) 55.69 ± 11.30 36–103
LDL-cholesterol (mg/dl) 128.40 ± 17.76 51–157
Triglyceridemia (mg/dl) 132.55 ± 18.21 82–158
WBC (cells/mm3) 7915 ± 351 7200–9200
Albumin (g/dl) 4.54 ± 0.24 3.98–4.9
Duration of the disease (months) 7 ± 1.78 4–12
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MMP-9 ELISA kit (Boster Biological Technology, LTD) and the Human TIMP-1 ELISA and Human103
TIMP-2 ELISA kit (Boster Biological Technology, LTD) in the entire group of subjects with venous104
leg ulcers.105
All the patients with venous leg ulcers were treated with a multi-layer bandaging system consisting106
of two anelastic bandage impregnated with oxide paste and coumarin (PRONTOZINK CUMARINA cm107
8 × 5 and 10 × 5 m PMA-Italia) and of two single stretch compression bandage (FISIODUR cm 8 × 5108
and 10 × 5 m PMA-Italia).109
Before and after the compression treatment, we measured the same parameters in the subgroup of110
patients with healed ulcers (14 women and 9 men, mean age 66.08 ± 12.33).111
3. Statistical analysis112
Data were expressed as means ± S.D.. The statistical difference between the whole group of subjects113
with venous leg ulcers and healthy controls was evaluated using the Student’s t test for unpaired data;114
the statistical difference regarding the plasma concentration of MMP-2, MMP-9, TIMP-1, and TIMP-2115
before and after healing was studied with the Student’s t test for paired data. The statistical difference116
between the subgroup of subjects with healed leg venous ulcers and healthy controls was performed117
employing the Student’s t test for unpaired data. The null hypothesis was rejected for p values < 0.05.118
4. Results119
Examining the whole group of subjects with leg venous ulcers in comparison with healthy controls,120
we found a significant increase in the plasma concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2;121
we also found an increase in MMP-2/TIMP-2 ratio even if no variation regarding MMP-9/TIMP-1 ratio122
was observed between the two groups (Table 2).123
In the subgroup of healed subjects we evaluated the plasma concentration of all these parameters124
before and after the healing of the venous ulcers and we observed that, after the healing, MMP-9,125
TIMP-2 and MMP-9/TIMP-1 ratio were decreased while no significant variation about MMP-2, TIMP-1126
and MMP-2/TIMP-2 ratio was found (Table 3).127
In addition, we also compared the subgroup of patients after the healing of leg ulcers with healthy128
controls and we found higher values of plasma concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2129
and of MMP-2/TIMP-2 ratio in this subgroup than in healthy controls (Table 4).130
Table 2
Means ± S.D. of gelatinase and gelatinase inhibitor plasma concentrations in control subjects
and in patients with venous ulcers
Control subjects Patients with venous ulcers
MMP-2 (ng/ml) 28.66 ± 4.15 48.66 ± 12.03∗∗∗
TIMP-2 (ng/ml) 85.67 ± 9.40 118.5 ± 9.15∗∗∗
MMP-9 (ng/ml) 51.55 ± 8.14 109.1 ± 18.73∗∗∗
TIMP-1 (ng/ml) 32.05 ± 4.80 60.02 ± 6.82∗∗∗
MMP-2/TIMP-2 0.338 ± 0.059 0.411 ± 0.099∗∗∗
MMP-9/TIMP-1 1.652 ± 0.376 1.850 ± 0.421
∗∗∗p < 0.001 vs control subjects (Student’s “t” test for unpaired data).
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Table 3
Means ± S.D. of gelatinase and gelatinase inhibitor plasma concentrations in patients whose
ulcers heal, at baseline and after healing
Baseline After ulcer healing
MMP-2 (ng/ml) 48.07 ± 12.40 44.04 ± 10.70
TIMP-2 (ng/ml) 117.4 ± 8.23 112.3 ± 7.49∗
MMP-9 (ng/ml) 109.4 ± 19.2 93.1 ± 20.8∗∗∗
TIMP-1 (ng/ml) 59.09 ± 6.78 57.66 ± 4.74
MMP-2/TIMP-2 0.410 ± 0.105 0.394 ± 0.100
MMP-9/TIMP-1 1.888 ± 0.456 1.628 ± 0.404∗∗
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 vs baseline (Student’s “t” test for paired data).
Table 4
Means ± S.D. of gelatinase and gelatinase inhibitor plasma concentrations in control subjects and
in patients with healed venous ulcers
Control subjects Patients with healed venous ulcers
MMP-2 (ng/ml) 28.66 ± 4.15 44.04 ± 10.70∗∗∗
TIMP-2 (ng/ml) 85.67 ± 9.40 112.3 ± 7.49∗∗∗
MMP-9 (ng/ml) 51.55 ± 8.14 93.1 ± 20.8∗∗∗
TIMP-1 (ng/ml) 32.05 ± 4.80 57.66 ± 4.74∗∗∗
MMP-2/TIMP-2 0.338 ± 0.059 0.394 ± 0.100∗
MMP-9/TIMP-1 1.652 ± 0.376 1.628 ± 0.404
∗p < 0.05; ∗∗∗p < 0.001 vs control subjects (Student’s “t” test for unpaired data).
5. Discussion131
In previous papers regarding several venous diseases, such as deep venous thrombosis [9, 19],132
post-thrombotic syndrome [7, 8] and leg venous ulcers [20], we demonstrated, especially after in vitro acti-133
vation with 4-phorbol 12-myristate 13-acetate (PMA) and with N-formyl-methionyl-leucyl-phenilalanine134
(fMLP), an evident alteration of the two parameters that reflect the rheology of the polymorphonuclear135
cells: the membrane fluidity, examined employing the fluorescent probe TMA-DPH, and the cytosolic136
calcium concentration, explored using the fluorescent probe Fura-2AM. In subjects with deep venous137
thrombosis [9] and leg venous ulcers [20] we also found an altered profile of the polymorphonuclear138
integrins (CD11a, CD11b, CD11c and CD18) at baseline and after activation with PMA and fMLP.139
These previous reports underline clearly the role played by polymorphonuclear cells in the pathogenesis140
and in the progression of chronic venous diseases and especially in venous ulcers.141
The results of this study add other information regarding the complex role of inflammation in venous142
ulcers. Up to now only few papers have regarded the evaluation of the plasma concentrations of gelatinases143
and their tissue inhibitors in this clinical condition [2, 28, 30] whereas more data are available regarding144
MMPs and their inhibitors in biopsies from damaged tissue [24] or in wound fluids of non-healers [22]145
and their behavior before and after some weeks of compression therapy [5, 23].146
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Our results seem to indicate that, although at baseline the gelatinases and their inhibitors are signifi-147
cantly increased in patients with venous leg ulcers, the healing of these ulcers, obtained with compression148
therapy, is associated with reduced plasma levels of MMP-9, TIMP-2 and also of MMP-9/TIMP-1 ratio.149
However, also in this subgroup of healed patients, the concentrations of gelatinases and their inhibitors150
are statistically elevated in comparison with healthy controls.151
Our data, together with literature data [2, 28, 30], besides to confirm the increase in plasma levels of152
MMPs and their inhibitors in venous ulcers, suggest that the healing partially influences their behavior.153
It is not possible to exclude a bidirectional relationship between the progression of chronic venous154
insufficiency towards ulcers and the trend of some MMPs, especially of those explored in the lesion155
tissue where they seem to play, directly or indirectly (increased transforming growth factor aˆ1, dermal156
fibroblast production), a specific role in the dynamics of extracellular matrix turnover, that may be retained157
responsible respectively for venous ulcers genesis and repair.158
At this regard it is also useful to underline the behavior of the plasma levels of tissue inhibitors in159
subjects with venous ulcers. In fact, from our data it is incontestable that the increase in gelatinases is160
accompanied by an analogous increase of their tissue inhibitors. This apparent dysregulation between161
gelatinases and their inhibitors might be imputable to their co-secretion or to a compensatory effect [13].162
Another aspect that must be underlined is that in this research we examined only the plasma levels of163
MMP-2 and MMP-9 and not their activity and this distinction is necessary especially considering the164
possible role of MMPs in this clinical condition.165
Bearing in mind this hypothesis, an obvious consideration may regard the possibility to pharmaco-166
logically interfere on these parameters in leg venous ulcers. In literature, up to now, some papers have167
regarded the action of the tetracyclines, and in particular of doxycycline, on MMPs in animal models of168
transient global cerebral ischemia [18] and vascular alterations related to arterial hypertension [10]. The169
same antibiotics seem to modulate MMPs activity, irrespective of their antimicrobial activity, in subjects170
with periodontitis, that is considered a risk factor for atherosclerotic cardiovascular events [14], as well as171
in cardiovascular diseases [11]. Doxacycline has been used at low doses also in the treatment of chronic172
venous ulcers [29] and it seems to accelerate their healing, even if it is not possible to exclude a role of173
the antimicrobial activity in the venous ulcers repair.174
In the treatment of venous ulcers other molecules able to interfere with MMPs activity might be175
employed: dipyridamole [15], an antiplatelet agents, cilostazol [12], a specific phosphodiesterase type176
III inhibitor with anti-atherosclerotic effect, and polyphenols [27], able to regulate the MMPs, and in177
particular the MMP-9.178
In conclusion, the plasma MMPs profile is impaired in subjects with venous leg ulcers and it improves179
after their healing, persisting anyway altered in comparison with healthy controls. Besides the compres-180
sion therapy, the employing of some molecules able to interfere with MMPs expression might be useful181
in venous ulcers treatment.182
This research complies with the requirement for ethical publication in Clinical Hemorheology and183
Microcirculation as published in Clin Hemorheol Microcirc. 2010;44(1):1–2.184
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